David A. Siegel Cassava Sciences Inc Transaction History

Two Sigma Advisers, LP

  • $42.5 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020
SELL
$3.26 - $9.65 $127,384 - $377,073
-39,075 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$1.1 - $6.12 $42,982 - $239,139
39,075 New
39,075 $203,000

Others Institutions Holding SAVA

# of Institutions
172
Shares Held
11.3M
Call Options Held
1.61M
Put Options Held
1.43M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $432M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email